- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04045548
Vaginal Dinoprostone Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System in Women With no Previous Vaginal Delivery
January 9, 2020 updated by: Ahmed Samy aly ashour, Cairo University
Benefits of Vaginal Dinoprostone Administration Prior to Levonorgestrel-releasing Intrauterine System Insertion in Women Delivered Only by Elective Cesarean Section: a Randomized Double-blind Clinical Trial.
To investigate whether vaginal dinoprostone administered before the levonorgestrel-releasing intrauterine system(IUs) insertion reduces failed insertions, insertion-related complications, and pain in Women With no Previous Vaginal Delivery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Long-acting reversible contraception methods are highly effective methods for reduction of the unplanned pregnancy rate worldwide.
The intrauterine device is a single procedure that provides reliable, effective and long term contraception for many women.
However, the insertion procedure can be associated with a troublesome degree of pain that prevent some women from choosing its use.
Different interventions have been described to decrease pain perception during intrauterine device insertion with no agreement on an effective one.
Study Type
Interventional
Enrollment (Actual)
200
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt, 11231
- Faculty of Medicine Cairo University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Non-pregnant women
- Women that did not receive any analgesics or Dinoprostone in the 24 hours prior to insertion
- Women who delivered only by cesarean section
Exclusion Criteria:
- Women with any uterine abnormalities as congenital anomalies, endometrial lesions, adenomyosis, fibroids.
- Those with a Category 3 or 4 conditions for intrauterine device insertion according to the WHO Medical Eligibility Criteria for contraceptive use
- Allergy to dinoprostone.
- Women refuse to participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: dinoprostone
1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 2 hours before IUD insertion.
|
1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
|
PLACEBO_COMPARATOR: placebo
one tablet of placebo inserted by the study nurse 2 hours before IUD insertion.
|
one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference in pain scores during intrauterine device insertion
Time Frame: 10 minutes
|
The difference in pain scores during intrauterine device insertion using visual analog scale from 0 to 10
|
10 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 10, 2019
Primary Completion (ACTUAL)
January 1, 2020
Study Completion (ACTUAL)
January 5, 2020
Study Registration Dates
First Submitted
August 2, 2019
First Submitted That Met QC Criteria
August 2, 2019
First Posted (ACTUAL)
August 5, 2019
Study Record Updates
Last Update Posted (ACTUAL)
January 13, 2020
Last Update Submitted That Met QC Criteria
January 9, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- dinoprostone IUD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrauterine Device
-
Assiut UniversityCompletedIntrauterine DeviceEgypt
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedIntrauterine DeviceTurkey
-
Assiut UniversityCompleted
-
Cairo UniversityCompletedIntrauterine DeviceEgypt
-
noha mohamed elzaydyUnknown
-
University of KentuckyDuramed ResearchWithdrawnIntrauterine Device Placement
-
Albert Einstein College of MedicineCompletedIntrauterine Device ExpulsionUnited States
-
Beni-Suef UniversityNot yet recruitingIntrauterine Contraceptive Device ComplicationEgypt
-
Cairo UniversityCompletedIntrauterine Contraceptive Device ComplicationEgypt
-
ALshaimaa Aboalhassan AliCompletedMechanical Complication of Intrauterine DeviceEgypt
Clinical Trials on Dinoprostone
-
Seoul National University HospitalCompletedNulliparous Women Who Scheduled for Labor InductionKorea, Republic of
-
Cairo UniversityCompletedDinoprostone TimingEgypt
-
Università degli Studi di BresciaCompletedLabor, Induced | Cervical RipeningItaly
-
Hospital Universitario 12 de OctubreInstituto de Salud Carlos III; Spanish Clinical Research Network - SCReNRecruitingFetal Growth RetardationSpain
-
Intermountain Health Care, Inc.Ferring PharmaceuticalsTerminatedInduction of Labor Affected Fetus / NewbornUnited States
-
Mednax Center for Research, Education, Quality...Completed
-
Weill Medical College of Cornell UniversityCompletedCervical Ripening | Labor InductionUnited States
-
Zeynep Kamil Maternity and Pediatric Research and...CompletedEarly Amniotomy, Unfavorable CervixTurkey
-
Clinical Hospital MerkurCompletedInduction of Labor Affected Fetus / Newborn | Prostaglandins Causing Adverse Effects in Therapeutic UseCroatia
-
Cairo UniversityCompletedIntrauterine DeviceEgypt